The p53 gene which encodes a nuclear phosphoprotein of 53 kDa, appears to be a frequent target for genetic abnormalities in a large number of human tumours. The p53 gene lies on chromosomal locus 17pl3.1 (Umesh et al., 1988) , where one allele is frequently deleted, and mutation often occurs on the remaining allele. These alterations of the p53 gene have been found in many human cancers, such as those of the colon (Baker et al., 1990; Rodriguez et al., 1990) , lung (Takahashi et al., 1989; Chiba et al., 1990) , breast (Prosser et al., 1990; Bartek et al., 1990) , liver (Fujimori et al., 1991; Slagle et al., 1991) and brain (Nigro et al., 1989) . Wild-type p53 product can suppress transformation in vitro, whereas mutated p53 protein may inactivate the wild-type p53 function, resulting in cell transformation (Finlay et al., 1989; Eliyahu et al., 1989; Baker et al., 1990) . These findings are consistent with the concept that the wild-type p53 gene product functions as a suppressor of neoplastic growth.
Although ovarian cancer is the leading cause of death among all carcinomas of the female reproductive tract, the genetic alterations involved in ovarian carcinoma remain largely unknown. As is the case with other common human carcinomas (Hunter, 1991) , accumulation of multiple genetic alterations must be present in ovarian carcinoma, playing significant roles in carcinogenesis and tumour progression. Amplification of the HER-21/neu (Slamon et al., 1989) , cmyc (Zhou et al., 1988) and c-K-ras (Filmus & Buick, 1985) genes has been detected in ovarian carcinoma, however the incidence of such amplifications is not high. On the other hand, some data are available on the alterations of p53 gene in ovarian carcinoma (Eccles et al., 1990 (Eccles et al., , 1992 ; Lee, 1990; Marks et al., 1991; Mazars et al., 1991; Okamoto et al., 1991) , but little information is available regarding the prognostic significance of the p53 gene abnormalities.
The present study was undertaken to examine alterations of the p53 gene in a series of 54 ovarian carcinomas using PCR-SSCP' analysis (Orita et al., 1989; Hayashi, 1991) . The utilisation of DNA samples extracted from paraffinembedded tissues prompted us to investigate retrospectively allelic losses and mutations of the p53 gene and their association with clinicopathological findings. A chemiluminescent detection system (Beck et al., 1989; Creasey et al., 1991) was adapted for PCR-SSCP analysis in order to eliminate the hazards and long exposure times associated with the original radioactive method. We examined p53 gene mutation not only in exons 5-8, where most of the evolutionarily conserved amino acids are concentrated (Hollstein et al., 1991) , but also in exon 4, where some mutations have been reported in ovarian cancer . We also detected allelic losses of p53 gene from a polymorphism in exon 4 (Buchman et al., 1988) represented by PCR-SSCP analysis (Orita et al., 1989; Okamoto et al., 1991 (Serov & Scully, 1973) . The clinical stage was evaluated according to the typing system of the International Federation of Gynecology and Obstetrics (FIGO, 1982) . (Jackson et al., 1991) . After complete digestion, DNA was purified by deproteination with saturated sodium chloride (Miller et al., 1988) and precipitation by ethanol. The concentration of DNA was spectrophotometrically determined, and the DNA solution at a concentration of 100 ng ml' was used as a template for the following PCR procedure.
To amplify coding exons 4-8 of the p53 gene, the following oligonucleotide primers were designed using published sequence data (Buchman et al., 1988) For SSCP analysis, a 2 pi aliquot of the PCR product was diluted 50-fold with a loading solution containing 20 mM EDTA, pH 8.0, 95% formamide, 0.05% bromophenol blue and 0.05% xylene cyanol. The diluted samples were heated at 90°C for 5 min, and 2 gd of the samples were applied to two non-denaturing polyacrylamide gels (0.5 x HydroLink MDE gel; AT Biochem, Malvern, PA, USA), one containing 5% glycerol and the other without glycerol. Electrophoresis in the gels with and without glycerol was performed at a constant power of 6 W for 12 h and 6 h respectively, at room temperature. Then, the DNA fragments in the gels were transferred to a nylon membrane (Immobilon-S; Millipore, Bedford, MA, USA) by capillary blotting for 30 min using 0.5 x Tris-borate buffer without any pretreatment of the gels. By this procedure, about a third of the DNA fragments was transferred to the membrane surface. The gels containing untransferred DNA fragments were stored at 370C in humidified air until cutting of the gel pieces containing a mobility-shift band. After transfer, the membrane was dried. and the DNA fragments were cross-linked to the membrane by ultraviolet irradiation (33,000 mJ cm2 at 254 nm). The bands of biotin-labelled DNA fragments were detected with a Plex 5 Chemiluminescent Subkit (New England BioLabs, Beverly, MA, USA) basically according to the report of Creasey et al. (1991) . The luminescing band patterns were recorded on standard X-ray film with an exposure time of 15-30 min. In the SSCP analysis for exon 4, the signal intensity of the bands was determined by a Bio Image 505 System (Millipore).
Sequencing analysis By laying the developed film of SSCP analysis on the stored gel, an area of the gel containing a mobility-shift band was determined and cut out. DNA fragments were eluted from excised gel slices by the crush and soak method (Sambrook et al., 1989) , and were amplified by a PCR under the same conditions as described above. The sequences of the primers used were identical to those used in the prior PCR but were not biotinylated. The PCR products were fractionated by electrophoresis through 12% non-denaturing polyacrylamide gels. The it was confirmed that the PCR fragment generated from the cloned DNA using the same set of primers migrated to the same position as the abnormal fragment generated from the respective cellular DNAs.
Statistics
Statistical analyses were done using Fisher's exact probability test or Student's t-test. Survival estimates were calculated using the product limit method of Kaplan and Meier (1956) .
Differences in survival were tested using the log-rank statistic (Mantel, 1966) .
Results

Allelic losses ofp53 gene
Since there is sequence polymorphism at codon 72 in exon 4 (Buchman et al., 1988) , the DNA fragment covering exon 4 was amplified by a PCR, and analysed by the SSCP method. Depending on the presence or absence of 5% glycerol in the gel, the mobilities and the separation patterns of allelic bands varied but they were evident and reproducible under each condition. Figure I shows the representative results of SSCP analysis of the gel without glycerol. Polymorphism at codon 72 in exon 4 was represented by three bands with different mobility. Sequence analysis revealed that the band on the top (band 1, B1) and the band in the middle (band 2, B2) contained the arginine codon (CGC) and the proline codon (CCC), respectively, and that the band at the bottom corresponded to each of the complementary strands which comigrated under these conditions. Allelic loss was able to be detected by PCR-SSCP analysis without corresponding normal tissues, because a residual weak signal, presumably derived from normal cells in the tumour specimen, was observed in most of the tumours with a -heterozygous genotype (for example cases 2, 3, 4, 7 and 8 in Figure 1 ). According to the criteria of Okamoto et al. (1991) , allelic loss is considered to have occurred if tumours show a heterozygous genotype and the signal intensity of a paired allelic fragment is less than 40% of the other paired fragments.
Signal intensity of one of the bands BI and B2 was reduced in 18 of the 26 ovarian carcinomas with a heterozygous genotype, indicating the presence of allelic loss (for example cases 2, 3, 4 and 8 in Figure 1) . Moreover, in six cases with a homozygous genotype and p53 gene mutation (cases 1, 5, 6, 9, 12 and 14 in Figure 1 and Table I In the SSCP analysis of the gel without glycerol, 14 ovarian carcinomas showed the bands with different mobility in one of the three PCR fragments (exons 5, 6 and 7 in Figure 2 ), whereas none of the walls of 14 benign ovarian cysts and three normal ovaries examined showed any band with different mobility. SSCP analysis of the gel containing 5% glycerol yielded the same result, although the pattern of separations of the bands was varied. When a normal allele is retained in the tumour, the intensity of bands for mutated allele should be the same as or less than that of bands for normal allele. In cases 1, 2, 4, 5, 6, 8, 9, 10, 11, 12 and 14 in Figure 2 , the intensity of bands with different mobility was higher than that of the corresponding normal bands, indicating the presence of loss of normal allele. However, in cases 3, 7 and 13 in Figure 2 , we were not able to detect any loss of normal allele, because the intensity of the band with different mobility was lower than that of the bands for normal allele.
In the 14 DNA samples showing bands with different mobility, sequence analyses were performed to confirm the presence of mutated p53 genes and to determine the type of mutations ( Figure 3 ). As summarised in Table I , sites of mutations were distributed between codons 143 and 249, mutations tended to cluster in exons 5 and 7 [9 of 14 in exon 7 (64%); 4 in exon 5 (29%); and I in exon 6 (7%)]; 11 (79%) of 14 mutations were detected on the highly conserved regions (Hollstein et al., 1991) , and the other three mutations were found at codons corresponding to amino acids conserved among several species (Hollstein et al., 1991) . Thirteen of the 14 cases with mutation had concomitant loss of the normal allele. Twelve mutations revealed single nucleotide substitutions (missense mutations), ten of which were transitions (from G:C to A:T in eight cases and from A:T to G:C in one case), and the other two were transversions from G to T. Cases 4 and 6 revealed a three-base deletion, resulting in the deletion of codons 218 (valine) and 234 (tyrosine) respec- (0%) (0%) (67%) (50%) (50%) cases of G:C to A: T transition, two cases of G to T transversion, two cases of three-base deletion and one case of A:T to G:C transition. On the other hand, G:C to A:T transitions were the most frequent substitution (4/5 cases) in endometrioid adenocarcinoma. No mutation was found in 12 clear cell carcinomas, three squamous cell carcinomas and one undifferentiated carcinoma.
We were able to evaluate p53 gene alteration in both the primary tumour and 1-3 metastases in three patients with allelic loss and mutation (cases 3, 8 and 12) and four patients with allelic loss but without mutation, in whom the tumour was obtained at the initial cytoreductive surgery. In all seven patients, the genetic alteration revealed in the metastases was identical to that in the primary tumour. We were also able to compare the status of the p53 gene before and after chemotherapy in three patients with allelic loss and mutation (cases 5, 7 and 12) and in three patients with allelic loss but without mutation, in whom the tumour was obtained at the second-look or subsequent laparotomy. The status of the p53 gene did not change during the course of post-operative chemotherapy in any of the six patients.
In Table III , the relation between p53 alteration and either histological grade or FIGO stage in serous tumours and endometrioid adenocarcinomas is shown. In ovarian serous tumours, allelic loss or the mutation of p53 gene was not detected in benign serous adenomas, whereas the incidence of mutation in serous cystadenocarcinoma was relatively high (8/19, 43%) and the incidence of the mutation seemed to be higher in accordance with de-differentiation. The incidence in FIGO III/IV seemed to be slightly higher than that in FIGO I/TI. In endometrioid adenocarcinoma, the incidence in moderately differentiated cases seemed to be higher than in well-differentiated cases. According to the FIGO stage, the incidence of p53 mutation in FIGO stage III/IV seemed to be higher than that in FIGO stage I/II.
One (8%) of the 12 evaluable patients with p53 gene mutation (six with progressive disease and six second looks) and four (17%) of the 24 evaluable patients without p53 gene mutation (nine with progressive disease and 15 second looks) revealed a negative second look; no relationship was found between the presence of p53 gene mutation and the incidence of surgically documented complete response (P> 0.4). Among the five patients who had a negative second-look laparotomy, one patient without p53 gene mutation has subsequently showed recurrence of the disease. The other three patients are alive with no evidence of the disease. Since most of the p53 gene mutations confirmed in this study were observed in serous cystadenocarcinoma and endometrioid adenocarcinoma (Table I) , we examined the relation between p53 gene mutation and survival time in 31 patients (19 patients with serous cystadenocarcinoma and 12 patients with endometrioid adenocarcinoma) (Figure 4 ). Although the median survival time of the 13 patients with p53 gene mutation (20.1 months) was somewhat worse than that of the 18 patients without p53 gene mutation (28.2 months), the difference normalised by clinical stage was not statistically significant (P> 0.5).
Discussion
Several reports Mashiyama et al., 1991; Tamura et al., 1991; D'Amico et al., 1992) have documented the effectiveness of PCR-SSCP analysis for detecting mutations of p53 gene. In this study we extracted DNA from paraffin-embedded tissues because PCR does not require high molecular weight DNA as a template. This approach makes possible retrospective analysis of tissue specimens several years old (Jackson et al., 1991) , although the length of DNA fragments that can be amplified by PCR depends on the integrity of the template DNA. Shorter DNA fragments are better suited for detection of mutations by SSCP analysis; the sensitivity of SSCP analysis is more than 99% for DNA fragments of 100-300 bp (Hayashi, 1991) . When the DNA fragments analysed by SSCP are less than approximately 300 bp, the possibility of a false-negative result is quite low under two conditions (Hayashi, 1991; Hayashi & Yandel, 1993) . The SSCP electrophoresis was performed in the gels with and without 5% glycerol in the present study. For these reasons, we performed PCRs on each of exons 4-8 of the p53 gene, resulting in successful SSCP analyses on most of the DNA samples extracted from paraffin-embedded tissues.
Using PCR-SSCP analysis, we detected allelic losses of the p53 gene in 24 (75%) of the 32 informative ovarian cancers, whereas, as expected, allelic loss was not detected in any of the seven benign ovarian cysts with heterozygous genotypes. The frequency of allelic loss in the ovarian cancers examined in this study was similar to that in the previous reports (Eccles et al., 1990; Lee et al., 1990; Okamoto et al., 1991) on loss of heterozygosity of chromosome 17 detected by restriction fragment length polymorphism analysis. We also found 14 cases with p53 gene mutation (26%) in 54 ovarian cancers. This frequency of mutation was lower than that of allelic loss, and not as high as those for carcinomas of the colon (Baker et al., 1990; Rodriguez et al., 1990) (Takahashi et al., 1989; Chiba et al., 1990) . We regard our value as a conservative estimate for the following reasons. All primers were designed such that they included several of the first or last nucleotides of exons (Buchman et al., 1988) . Therefore, mutations occurring in the regions included in the primers, such as splice site mutation, could not be detected. It is also possible that mutations might be present in a region of p53 gene that was not targeted in the present study. Furthermore, there may be undetectable mutations by SSCP analysis, because the strands with different sequences sometimes have the same stable conformation and co-migrate, as in the case of exon 4 (Figure 1 ). We also cannot rule out the possibility that genetic mutations are masked by a high proportion of non-cancerous cells contained in tumour specimens. Sequence analysis revealed 12 single point mutations and two deletions. Nine cases had not only p53 gene mutations in the highly conserved regions of p53 gene, but also allelic losses of p53 gene, strongly suggesting the complete loss of normal p53 function. Most of the p53 gene mutations confirmed in this study were observed in serous cystadenocarcinoma and endometrioid adenocarcinoma. In serous tumours, no alterations of p53 gene could be detected in benign serous cystadenomas. From the point of view of relationship between differentiation and p53 alteration in serous tumours, the incidence of the alteration seemed to be increased in accordance with de-differentiation. In endometrioid adenocarcinoma, a similar tendency was also found.
The nucleotide changes were not confined to a specific pattern in serous cystadenocarcinoma. In contrast, G:C to A:T transitions constitute the majority of mutations in endometrioid adenocarinoma. The pattern of mutations seen in the present study is similar to that reported for other epithelial tumours, and the frequency of the G:C to A:T transversion in ovarian endometrioid adenocarcinoma is considered to resemble to that in hepatocellular carcinomas (Caron de Fromentel & Soussi, 1992) . No mutation was detected in 12 clear cell carcinomas, in agreement with the result of Okamoto et al. (1991) . It is probable that the disparity between these mutational spectra is due to differences in metabolic and DNA repair capacities among different cell types (Harris, 1989) . One of the features of the p53 mutational spectra in human cancers is that transitions at CpG dinucleotides contribute heavily to the mutational frequency in many cancers (Hollstein et al., 1991) . In the present series of ovarian cancer, transitions at CpG sites were found in four (29%) of 14 mutations, and this frequency was relatively low compared with that of colon cancer (67%) (27) . Methylation of CpG sites and the level of spontaneous deamination may differ in various tissue types. Eccles et al. (1992) reported the relation between immunohistochemical overexpression of p53 protein in frozen sections and allele loss at 17p in ovarian carcinoma. Their hypothesis using immunohistochemistry could be confirmed by the SSCP and direct sequencing in the present study. In particular, in ovarian serous tumorigenesis in the present study, allelic loss or mutation of p53 gene was not detected in benign serous adenoma, whereas the incidence of alteration in serous cystadenocarcinoma was relatively high (43%) and the incidence of the alteration seemed to be higher in accordance with de-differentiation. Recent work on colorectal tumours (Baker et al., 1990b) suggested that alteration of the p53 gene might be the rate-limiting step in tumorigenesis. Thus, in ovarian serous tumorigenesis, the point mutation in the p53 gene might be the rate-limiting step and the loss of the remaining wild-type allele might occur afterwards as a tumour changes from benign to malignant.
In this study, we determined whether p53 gene mutation correlated with prognostic factors in ovarian cancer. As a result, no correlation was revealed between p53 gene mutation and histological grade, which has been used with some success for predicting the eventual clinical outcome (Ozols et al., 1992) . We also found no relationship between p53 gene mutation and response to primary therapy. No correlation was found between p53 gene mutation and survival time in the 31 patients with serous cystadenocarcinoma or endometrioid adenocarcinoma, with or without cases with the mutations identified.
The present study suggests that alterations of the p53 gene might be involved in the development of a proportion of ovarian carcinomas, especially in serous tumorigenesis, and might play an important role in commencement of invasion. However, they could not have an important role as a mechanism for aggressive biological behaviour of the disease. Further investigations will be required to elucidate the multiple genes, oncogenes and tumour-suppressor genes involved in the ovarian carcinogenesis and to understand their biological and clinical significance.
